NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.
PAR-24-089
Award Ceiling
$750K
Closes
Nov 13, 2026
17d left
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This NOFO will not support efficacy or effectiveness trials, nor will
PAR-25-270
Award Ceiling
$1.1M
Closes
Nov 13, 2026
17d left
NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same target engagement measure; or study the impact of the natural product in a population that is more responsive,
PAR-25-269
Award Ceiling
$350K
Closes
Nov 13, 2026
17d left
NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated mid-phase clinical trials of natural products(i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. All applications submitted under this NOFO must be supported by sufficient preliminary data demonstrating bioavailability (if applicable) and documentation that the natural product produces a reproducible and measurable impact on target engagement (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure target engagement in the patient population of interest or when there is a fundamental understanding of the products mechanism of action will this preliminary data requirement be waived. Applications submitted to this NOFO should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site efficacy trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy trial. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This NOFO will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NO
PAR-25-271
Award Ceiling
$350K
Closes
Nov 13, 2026
17d left
Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
<p>The purpose of this NOFO is to continue the Physiology of the Weight Reduced State (POWERS) clinical trial. The goal of POWERS is to understand the physiological processes underlying individual variability in weight regain following weight loss due to a lifestyle intervention. The continuation of POWERS will allow for the completion of the ongoing clinical trial and to conduct analysis of collected data and biospecimens.</p><p>This NOFO invites a single source application from the Data Coordinating Center for the POWERS consortium. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application will be peer-reviewed, and only meritorious application(s) will be considered for funding.</p>
RFA-DK-27-122
Award Ceiling
—
Closes
Nov 17, 2026
21d left
Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
<p>The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application.</p>
PAR-25-274
Award Ceiling
—
Closes
Nov 17, 2026
21d left
NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health.
PAR-25-267
Award Ceiling
$350K
Closes
Nov 17, 2026
21d left
Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
<p>This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO.</p>
PAR-25-268
Award Ceiling
—
Closes
Nov 17, 2026
21d left
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (TEMP-23832, the R34 option).
PAR-25-158
Award Ceiling
—
Closes
Nov 17, 2026
21d left
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.
PAR-25-226
Award Ceiling
—
Closes
Nov 19, 2026
23d left
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.
PAR-25-052
Award Ceiling
—
Closes
Nov 19, 2026
23d left
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit the development of innovative senescence technologies (SenTecs), or the adaptation of existing technologies focused on identification, characterization and understanding the biological consequences of senescent cell (SnC) heterogeneity in the context of the tissue environments and secretomes to facilitate novel strategies for modulating SnCs in vivo and for predicting the outcomes of targeting SnCs in human aging and in disease conditions. These are five-year, milestone-driven awards consisting of two phases. The first two years constitute the UG3 phase and are focused on SenTec development and demonstration of technology feasibility. The following 3-years is the SenTec application UH3 phase where SenTecs continue to be optimized, refined and validated. In the final year of the UH3 award, SenTecs will undertake a demonstration project conducted in a collaborative effort within SenNet to provide further validation of the proposed SenTec. Applicants are required to submit both UG3 and UH3 projects together when responding to this NOFO. Transition from the UG3 to UH3 phases is not automatic and will occur only after administrative review of each SenTec at the close of Year 2 of the award.
RFA-RM-27-007
Award Ceiling
$6.0M
Closes
Nov 23, 2026
27d left
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support SenNet Discovery and Validation Centers (SenNet DVCs) as a core component of Stage 2 of the NIH Common Fund Cellular Senescence Network (SenNet). Building on Stage 1 resources, DVCs will define, refine, and validate tissue- and disease-relevant cellular senescence signatures (“senotypes”) and associated biomarkers, and will investigate their functional consequences in human health and disease. DVCs are expected to generate and contribute high-quality molecular, cellular, and spatial datasets (including relevant metadata and documentation) and to use complementary experimental systems, as appropriate, to validate senotypes/biomarkers and characterize responses to senescence-associated perturbations or senotherapeutic approaches. DVC applications should also propose goals and aims for SenNet consortium-wide organizational and outreach activities (SenNet OOC functions).</p>
RFA-RM-27-016
Award Ceiling
—
Closes
Nov 23, 2026
27d left
Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (SenNet DCIC) (UM1 Clinical Trials Not Allowed)
<p>The purpose of this Notice of Funding Opportunity (NOFO) is to support the SenNet Data Coordination and Integration Center (SenNet DCIC) as a core component of Stage 2 of the NIH Common Fund Cellular Senescence Network (SenNet). The DCIC will enable timely, high-quality submission, harmonization, integration, and broad dissemination of SenNet-generated data and associated resources by developing and implementing consortium-wide policies, standards, and workflows for data formats, metadata, quality control, and release. The DCIC will maintain and enhance SenNet’s data infrastructure (e.g., portal and associated tools) to support data discovery, access, analysis, visualization, and reuse, and will integrate Stage 1 and Stage 2 outputs to support atlasing and cross-study comparability. DCIC applications should also propose goals and aims for SenNet consortium-wide organizational and outreach activities (SenNet OOC functions).</p>
RFA-RM-27-025
Award Ceiling
$3.0M
Closes
Nov 23, 2026
27d left
Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
<p>The National Institutes of Health (NIH) hereby notifies NIH award recipients that funds may be available for revision applications to support the expansion of existing projects and/or programs within the awarding IC identified in the competitive revision Notice of Special Interest (NOSI). Applications for Revisions will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria. Only applications submitted in response to a NOSI published by an NIH Institute or Center will be allowed to apply to this NOFO.</p>
PA-23-317
Award Ceiling
—
Closes
Nov 24, 2026
28d left
National Center for Construction Safety and Health Research and Translation (U54)
<p>NIOSH is encouraging the submission of an application from qualified organizations for a National Center for Construction Safety and Health Research and Translation. Applicants are encouraged to propose multidisciplinary approaches and coordination for impactful applied and intervention research, hazard identification, and controls; develop partnerships for implementing prevention and intervention activities; and serve as a leader in research translation and research-to-practice for the protection of construction workers in the U.S. The Center will accomplish these goals by integrating and advancing research, research translation, best practices, policy and guidance, and capacity building. Center work should consider the NIOSH strategic plan and NORA construction research objectives. Center structure should take advantage of diverse scientific resources and focus on national worker safety and health issues. Centers should emphasize the creation and implementation of evidence-based solutions that address important construction industry safety and health problems. Collaborations with other academic institutions, nonprofit organizations, and other occupational safety and health-focused groups are expected. Applicants must concisely describe the occupational health burden of important safety and health issues in the construction industry and discuss how focused research and outreach activities will help alleviate the burden and reduce numbers. Applicants should also clearly articulate the anticipated impacts of the Center’s proposed work, both during the project period and beyond.</p>
RFA-OH-24-001
Award Ceiling
$5.8M
Closes
Dec 1, 2026
35d left
Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
This NOFO seeks to advance research and training in high-priority areas of child health by stimulating the use of Environmental Influences on Child Health Outcomes (ECHO) Cohort data by postdoctoral fellows from relevant scientific disciplines. This RFA will provide opportunities for fellows to study child health outcomes through the analysis of ECHO's large longitudinal data sets within the NICHD Data and Specimen Hub (DASH) repository. ECHO's DASH dataset integrates de-identified longitudinal data from more than 71,000 participants across the U.S. Prenatal and child exposure data include physical, chemical, social, behavioral, and biological factors. ECHO's five primary pediatric outcome areas are pre-, peri-, and postnatal outcomes, upper and lower airway, obesity, neurodevelopment, and positive health.
RFA-OD-27-008
Award Ceiling
$1.3M
Closes
Dec 2, 2026
36d left
Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21)
<p>The World Trade Center (WTC) Health Program supports exploratory and developmental research projects (R21) that address issues related to diagnostic or treatment uncertainty among individuals receiving monitoring and/or treatment under Subtitle C of the James Zadroga 9/11 Health and Compensation Act of 2010, as amended. This R21 Notice of Funding Opportunity (NOFO) is intended to encourage exploratory/developmental research by supporting the early and conceptual stages of project development to assess the feasibility of new areas of investigation with the potential to improve treatment effectiveness and diagnostic practices. These studies may lead to breakthroughs in a particular area or to the development of new interventions, techniques, agents, methodologies, models, or approaches with potential clinical impact. They are expected to break new ground or extend prior discoveries in new directions or applications. Applicants are expected to propose research for which there is likely to be minimal or no preliminary data.</p>
RFA-OH-26-015
Award Ceiling
$365K
Closes
Dec 8, 2026
42d left
Cooperative Research Agreements Related to the World Trade Center Health Program (U01)
<p>The National Institute for Occupational Safety and Health (NIOSH) supports research projects that address: (1) physical and mental health conditions related to the September 11, 2001, terrorist attacks; (2) diagnosing conditions for which there has been diagnostic uncertainty; and (3) treating conditions for which there has been treatment uncertainty. Conditions may have emerged since the treatment program began or since the WTC Health Program was established. This announcement solicits meritorious and scientifically rigorous applications that will: 1) improve diagnosis and treatment activities of the WTC Health Program; 2) expand knowledge about health effects related to the September 11, 2001, terrorist attacks; 3) answer critical questions about WTC-related physical and mental health conditions; and 4) apply lessons learned to improve response to future disasters. Potential projects may include, but are not limited to: (a) Screening research to evaluate current methods or facilitate the development of new or improved methods to detect disorders or health conditions; (b) Diagnostic research to evaluate current methods or facilitate the development of new or improved methods to identify diseases, disorders, or conditions; (c) Treatment research to evaluate or identify improved treatment interventions or methods, or to promote development of new or novel approaches; (d) Prevention research to identify or evaluate methods and interventions that prevent or mitigate the development or recurrence of diseases or disorders; (e) Quality of life research to identify, develop, or evaluate methods or interventions that improve comfort and quality of life for individuals with chronic illness or multimorbidity; (f) Omics research to improve methods for predicting disorders by identifying and understanding relationships between genes and illness (e.g., phenotypes and biomarkers), including how genetic factors influence disease development or response to treatment; (g) Epidemiologic or clinical research to identify patterns, causes, and control of adverse health effects among the 9/11-exposed population; (h) Health services research to examine access to care, cost of care, and outcomes associated with care delivery; (i) Implementation research to evaluate how research findings are disseminated, adopted, implemented, sustained, and scaled in real-world settings; and (j) Epidemiologic research to investigate emerging conditions where preliminary data suggest, but do not confirm, a causal relationship between 9/11 exposure and the condition. Examples can be found at https://www.cdc.gov/wtc/received.html.</p>
RFA-OH-26-001
Award Ceiling
$550K
Closes
Dec 8, 2026
42d left
Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)
<p>The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications to develop, apply, and test predictive models and perform integrative analyses to determine the impact of genomic variation on genome function. Centers funded through this initiative will become a part of the Impact of Genomic Variation on Function (IGVF) Consortium. As consortium members, centers will work together to ensure all consortium resources are accessible to a wide variety of potential users. Centers also will collaborate with other consortium components to guide and optimize IGVF experimental design, to provide analytical expertise and support for consortium-wide efforts, and to develop and execute shared analysis strategies to meet consortium goals.</p>
RFA-HG-27-010
Award Ceiling
$800K
Closes
Dec 14, 2026
48d left